Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment (vol 10, pg 531, 2023)

被引：0
|
作者：
McGrattan, Katlyn E.
Shell, Richard D.
Hurst-Davis, Rebecca
Young, Sally Dunaway
O'Brien, Eamonn
Lavrov, Arseniy
Wallach, Shiri
LaMarca, Nicole
Reyna, Sandra P.
Darras, Basil T.
机构：
来源：
JOURNAL OF NEUROMUSCULAR DISEASES | 2023年 / 10卷 / 05期
关键词：
D O I：
10.3233/JND-239002
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：985 / 986
页数：2
相关论文
共 50 条
  • [1] Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment
    McGrattan, Katlyn E.
    Shell, Richard D.
    Hurst-Davis, Rebecca
    Young, Sally Dunaway
    O'Brien, Eamonn
    Lavrov, Arseniy
    Wallach, Shiri
    LaMarca, Nicole
    Reyna, Sandra P.
    Darras, Basil T.
    JOURNAL OF NEUROMUSCULAR DISEASES, 2023, 10 (04) : 531 - 540
  • [2] Bulbar function for patients with spinal muscular atrophy type 1 following onasemnogene abeparvovec
    McGrattan, K.
    Shell, R.
    Hurst-Davis, R.
    Young, S. Dunaway
    O'Brien, E.
    Lavrov, A.
    Wallach, S.
    LaMarca, N.
    Reyna, S.
    Darras, B.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S85 - S85
  • [3] Acute Benign Myositis Following Onasemnogene Abeparvovec Therapy in Type 1 Spinal Muscular Atrophy
    Dosi, Claudia
    Tozzo, Alessandra
    Masson, Riccardo
    PEDIATRIC NEUROLOGY, 2022, 131 : 23 - 24
  • [4] Cost comparison analysis of onasemnogene abeparvovec and nusinersen for treatment of patients with spinal muscular atrophy type 1 in the Netherlands
    van der Schans, Simon
    Velikanova, Rimma
    Weidlich, Diana
    Howells, Ruth
    Patel, Anish
    Bischof, Matthias
    Postma, Maarten J.
    Boersma, Cornelis
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2025,
  • [5] Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
    Chand, Deepa
    Mohr, Franziska
    McMillan, Hugh
    Tukov, Francis Fonyuy
    Montgomery, Kyle
    Kleyn, Aaron
    Sun, Rui
    Tauscher-Wisniewski, Sitra
    Kaufmann, Petra
    Kullak-Ublick, Gerd
    JOURNAL OF HEPATOLOGY, 2021, 74 (03) : 560 - 566
  • [6] Meta-analysis of clinical impact of onasemnogene abeparvovec treatment of spinal muscular atrophy patients
    Reyna, S.
    Dabbous, O.
    Wallach, S.
    Patel, A.
    Toro, W.
    Ritter, S.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [7] Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1
    Bischof, Matthias
    Lorenzi, Maria
    Lee, Jennifer
    Druyts, Eric
    Balijepalli, Chakrapani
    Dabbous, Omar
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (10) : 1719 - 1730
  • [8] Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis
    Pascual-Morena, Carlos
    Cavero-Redondo, Ivan
    Luceron-Lucas-Torres, Maribel
    Martinez-Garcia, Irene
    Rodriguez-Gutierrez, Eva
    Martinez-Vizcaino, Vicente
    HUMAN GENE THERAPY, 2023, 34 (3-4) : 129 - 138
  • [9] Efficacy and safety of onasemnogene abeparvovec for the treatment of patients with spinal muscular atrophy type 1: A systematic review with meta-analysis
    Fernandes, Brigida Dias
    Krug, Barbara Correa
    Rodrigues, Fernanda D'Athayde
    Cirilo, Herica Nubia Cardoso
    Borges, Stefani Sousa
    Schwartz, Ida Vanessa D.
    Probst, Livia Fernandes
    Zimmermann, Ivan
    PLOS ONE, 2024, 19 (05):
  • [10] Outcomes of Children Treated With Nusinersen/Onasemnogene Abeparvovec for Pediatric Spinal Muscular Atrophy Type 1
    Chacko, A.
    Sly, P. D.
    Gauld, L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
12345